US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TRAWS PHARMA

1.48

-0.0400-2.63%

Post-market: 1.480.00000.00%19:46 EDT

Volume:18.31K

Turnover:27.55K

Market Cap:8.24M

PE:-0.13

High:1.53

Open:1.52

Low:1.48

Close:1.52

52wk High:19.44

52wk Low:0.9700

Shares:5.56M

Float Shares:3.77M

Volume Ratio:0.45

T/O Rate:0.49%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-11.2238

EPS(LYR):-35.2126

ROE:-2331.25%

ROA:-83.59%

PB:1.37

PE(LYR):-0.04

Loading ...

Overview Company News Filings

BRIEF-Nora Brennan Resigns As Traws Pharma's Interim CFO

Traws Pharma Inc. Announces Departure of Interim CFO Nora Brennan and Appointment of Charles Parker as Successor

BRIEF-Traws Pharma Advances Antiviral Pipeline With Multiple Regulatory Submissions

BRIEF-Traws Pharma Announces Receipt Of FDA Guidance On Tivoxavir Marboxil, Plans For Pursuing Stockpiling For Pandemic Preparedness

BRIEF-Traws Pharma Reports First Quarter 2025 Results And Business Highlights

Traws Pharma Q1 EPS $2.09 Beats $(8.04) Estimate, Sales $57.00K Miss $60.00K Estimate

Traws Pharma Inc. Reports Q1 2025 Results: Revenue Steady at $57K, Net Income Soars to $21.5M, EPS at $2.17

Press Release: Traws Pharma Reports Full Year 2024 Results and Business Highlights

Traws Pharma CEO Werner Cautreels Retires, Chair Iain Duke Succeeds on Interim Basis

MT Newswires Live

Traws Pharma CEO Werner Cautreels retires, Iain Dukes named interim CEO

Traws Pharma Announces Management Updates

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates

BRIEF-Traws Pharma Presents Positive Data For TXM As Bird Flu Treatment At ICAR

Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

BRIEF-Traws Pharma Enters $50 Million ATM Agreement With Citizens JMP Securities

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

BRIEF-Traws Pharma Reports Positive Results From Accepted Bird Flu Model For Anti-Viral Candidate, Tivoxavir Marboxil

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TRAW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TRAW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAW\",,,,,undefined,":{"symbol":"TRAW","market":"US","secType":"STK","nameCN":"TRAWS PHARMA","latestPrice":1.48,"timestamp":1754596800000,"preClose":1.52,"halted":0,"volume":18308,"hourTrading":{"tag":"盘后","latestPrice":1.48,"preClose":1.48,"latestTime":"19:46 EDT","volume":45,"amount":68.44,"timestamp":1754610388676},"delay":0,"floatShares":3774543,"shares":5564315,"eps":-11.223835,"marketStatus":"Closed","change":-0.04,"latestTime":"08-07 16:00:00 EDT","open":1.5242,"high":1.5316,"low":1.48,"amount":27553.2434104,"amplitude":0.033947,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-11.223835,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1754640000000},"marketStatusCode":5,"adr":0,"listingDate":1374724800000,"exchange":"NASDAQ","adjPreClose":1.52,"preHourTrading":{"tag":"盘前","latestPrice":1.57,"preClose":1.52,"latestTime":"08:35 EDT","volume":1676,"amount":2635.0083732,"timestamp":1754570131670},"postHourTrading":{"tag":"盘后","latestPrice":1.48,"preClose":1.48,"latestTime":"19:46 EDT","volume":45,"amount":68.44,"timestamp":1754610388676},"volumeRatio":0.448332,"impliedVol":1.6331,"impliedVolPercentile":0.9688},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAW\",,,,,undefined,":{"symbol":"TRAW","floatShares":3774543,"roa":"-83.59%","roe":"-2331.25%","lyrEps":-35.212551,"volumeRatio":0.448332,"shares":5564315,"dividePrice":0,"high":1.5316,"amplitude":0.033947,"preClose":1.52,"low":1.48,"week52Low":0.97,"pbRate":"1.37","psRate":"36.28","week52High":19.44,"institutionHeld":0,"latestPrice":1.48,"eps":-11.223835,"divideRate":0,"volume":18308,"delay":0,"ttmEps":-11.223835,"open":1.5242,"prevYearClose":8.88,"prevWeekClose":1.46,"prevMonthClose":1.54,"prevQuarterClose":1.48,"fiveDayClose":1.54,"twentyDayClose":1.57,"sixtyDayClose":1.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TRAW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"TRAW","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":2.09},{"market":"US","date":"2025-03-31","symbol":"TRAW","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":95.66},{"market":"US","date":"2024-11-14","symbol":"TRAW","fiscalQuarterEnding":"2024/09","expectedEps":-6.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-8.81},{"market":"US","date":"2024-09-23","symbol":"TRAW","defaultRemindTime":1727098200000,"type":"split","dateTimestamp":1727064000000,"forFactor":25,"toFactor":1,"ratio":25},{"market":"US","date":"2024-08-15","symbol":"TRAW","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723694400000,"reportTimeType":"pre","actualEps":-4.87}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TRAW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TRAW\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TRAW\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TRAW","date":"2025-08-06","current":-0.060788,"percent":0.813291,"low":-0.930105,"twenty":-0.511335,"median":-0.090759,"eighty":-0.061265,"high":-0.033516,"avg":-0.231749,"sd":0.268156,"marketCap":8513401},"quantilePoints":[{"date":"2024-04-05","current":-0.930105,"twenty":-0.930105,"median":-0.930105,"eighty":-0.930105,"marketCap":17623624},{"date":"2024-04-12","current":-0.875242,"twenty":-0.899279,"median":-0.879971,"eighty":-0.87246,"marketCap":16584087},{"date":"2024-04-19","current":-0.774197,"twenty":-0.884701,"median":-0.859217,"eighty":-0.774642,"marketCap":14669484},{"date":"2024-04-26","current":-0.703922,"twenty":-0.875242,"median":-0.784323,"eighty":-0.745597,"marketCap":13337908},{"date":"2024-05-03","current":-0.713993,"twenty":-0.87246,"median":-0.75973,"eighty":-0.713993,"marketCap":13528735},{"date":"2024-05-10","current":-0.722239,"twenty":-0.859217,"median":-0.743093,"eighty":-0.71377,"marketCap":13684982},{"date":"2024-05-17","current":-0.7463,"twenty":-0.799236,"median":-0.738475,"eighty":-0.713993,"marketCap":13549821},{"date":"2024-05-24","current":-0.73457,"twenty":-0.794005,"median":-0.741761,"eighty":-0.718444,"marketCap":13336853},{"date":"2024-05-31","current":-0.675921,"twenty":-0.778515,"median":-0.736522,"eighty":-0.713681,"marketCap":12272014},{"date":"2024-06-07","current":-0.836261,"twenty":-0.794624,"median":-0.73457,"eighty":-0.711322,"marketCap":15183160},{"date":"2024-06-14","current":-0.873049,"twenty":-0.83888,"median":-0.740589,"eighty":-0.71288,"marketCap":15851082},{"date":"2024-06-21","current":-0.649387,"twenty":-0.836845,"median":-0.738475,"eighty":-0.709541,"marketCap":11790270},{"date":"2024-06-28","current":-0.62709,"twenty":-0.83835,"median":-0.738475,"eighty":-0.706993,"marketCap":11385454},{"date":"2024-07-05","current":-0.557395,"twenty":-0.836651,"median":-0.734469,"eighty":-0.698614,"marketCap":10120072},{"date":"2024-07-12","current":-0.483661,"twenty":-0.814046,"median":-0.728873,"eighty":-0.672205,"marketCap":8781358},{"date":"2024-07-15","current":-0.554747,"twenty":-0.806641,"median":-0.726171,"eighty":-0.663181,"marketCap":10071990},{"date":"2024-08-02","current":-0.532446,"twenty":-0.799236,"median":-0.724978,"eighty":-0.649387,"marketCap":9667086},{"date":"2024-08-09","current":-0.491259,"twenty":-0.797102,"median":-0.722239,"eighty":-0.600613,"marketCap":8919304},{"date":"2024-08-16","current":-0.066488,"twenty":-0.794005,"median":-0.718444,"eighty":-0.532446,"marketCap":9112137},{"date":"2024-08-23","current":-0.065565,"twenty":-0.774642,"median":-0.71377,"eighty":-0.508851,"marketCap":8985580},{"date":"2024-08-30","current":-0.06743,"twenty":-0.774197,"median":-0.709986,"eighty":-0.494812,"marketCap":9241226},{"date":"2024-09-06","current":-0.06538,"twenty":-0.762623,"median":-0.702951,"eighty":-0.490604,"marketCap":8960268},{"date":"2024-09-13","current":-0.062794,"twenty":-0.758648,"median":-0.694503,"eighty":-0.071087,"marketCap":8605907},{"date":"2024-09-20","current":-0.057254,"twenty":-0.751084,"median":-0.683063,"eighty":-0.068232,"marketCap":7846562},{"date":"2024-09-27","current":-0.081301,"twenty":-0.74722,"median":-0.649387,"eighty":-0.067774,"marketCap":11142278},{"date":"2024-10-04","current":-0.073971,"twenty":-0.746382,"median":-0.624791,"eighty":-0.068232,"marketCap":10137646},{"date":"2024-10-11","current":-0.065174,"twenty":-0.745738,"median":-0.557395,"eighty":-0.067596,"marketCap":8932088},{"date":"2024-10-18","current":-0.062642,"twenty":-0.744673,"median":-0.543597,"eighty":-0.067316,"marketCap":8585034},{"date":"2024-10-25","current":-0.111702,"twenty":-0.743234,"median":-0.515682,"eighty":-0.066488,"marketCap":15308680},{"date":"2024-10-31","current":-0.109715,"twenty":-0.741526,"median":-0.508851,"eighty":-0.066652,"marketCap":15036392},{"date":"2024-11-08","current":-0.111592,"twenty":-0.739321,"median":-0.498158,"eighty":-0.06682,"marketCap":15293553},{"date":"2024-11-15","current":-0.123204,"twenty":-0.736132,"median":-0.492107,"eighty":-0.067201,"marketCap":16884930},{"date":"2024-11-22","current":-0.096923,"twenty":-0.734509,"median":-0.489621,"eighty":-0.06743,"marketCap":13645248},{"date":"2024-11-29","current":-0.098427,"twenty":-0.734469,"median":-0.48099,"eighty":-0.067496,"marketCap":13857037},{"date":"2024-12-06","current":-0.108407,"twenty":-0.733312,"median":-0.130241,"eighty":-0.067596,"marketCap":15262104},{"date":"2024-12-13","current":-0.104014,"twenty":-0.729414,"median":-0.121316,"eighty":-0.067685,"marketCap":14643681},{"date":"2024-12-20","current":-0.114642,"twenty":-0.725217,"median":-0.114642,"eighty":-0.068025,"marketCap":16139817},{"date":"2024-12-27","current":-0.244993,"twenty":-0.723719,"median":-0.117501,"eighty":-0.068353,"marketCap":34491315},{"date":"2025-01-03","current":-0.186323,"twenty":-0.723452,"median":-0.123204,"eighty":-0.068427,"marketCap":26231553},{"date":"2025-01-10","current":-0.173429,"twenty":-0.722482,"median":-0.130241,"eighty":-0.069344,"marketCap":24416220},{"date":"2025-01-17","current":-0.146996,"twenty":-0.721141,"median":-0.147157,"eighty":-0.069786,"marketCap":20694789},{"date":"2025-01-24","current":-0.13797,"twenty":-0.719413,"median":-0.140763,"eighty":-0.070056,"marketCap":19424056},{"date":"2025-01-31","current":-0.156666,"twenty":-0.718444,"median":-0.146996,"eighty":-0.070643,"marketCap":22056288},{"date":"2025-02-07","current":-0.178157,"twenty":-0.715773,"median":-0.153981,"eighty":-0.07105,"marketCap":25081842},{"date":"2025-02-14","current":-0.173739,"twenty":-0.713859,"median":-0.157526,"eighty":-0.072709,"marketCap":24459897},{"date":"2025-02-21","current":-0.121618,"twenty":-0.713592,"median":-0.156666,"eighty":-0.073848,"marketCap":17121928},{"date":"2025-02-28","current":-0.087129,"twenty":-0.71288,"median":-0.149414,"eighty":-0.074131,"marketCap":12266456},{"date":"2025-03-07","current":-0.070533,"twenty":-0.710432,"median":-0.144632,"eighty":-0.071013,"marketCap":9929988},{"date":"2025-03-14","current":-0.07157,"twenty":-0.706225,"median":-0.135069,"eighty":-0.071013,"marketCap":10076017},{"date":"2025-03-21","current":-0.074682,"twenty":-0.703145,"median":-0.130241,"eighty":-0.070984,"marketCap":10514105},{"date":"2025-03-28","current":-0.066643,"twenty":-0.70173,"median":-0.123448,"eighty":-0.070533,"marketCap":9382378},{"date":"2025-04-04","current":-0.066422,"twenty":-0.698614,"median":-0.121618,"eighty":-0.069679,"marketCap":11060862},{"date":"2025-04-11","current":-0.053321,"twenty":-0.692996,"median":-0.117957,"eighty":-0.068372,"marketCap":8879132},{"date":"2025-04-17","current":-0.060633,"twenty":-0.690629,"median":-0.115407,"eighty":-0.067596,"marketCap":10096842},{"date":"2025-04-25","current":-0.046618,"twenty":-0.687348,"median":-0.111751,"eighty":-0.066971,"marketCap":7762898},{"date":"2025-05-02","current":-0.042961,"twenty":-0.674063,"median":-0.111618,"eighty":-0.066488,"marketCap":7154043},{"date":"2025-05-09","current":-0.042657,"twenty":-0.663181,"median":-0.111481,"eighty":-0.065417,"marketCap":7103306},{"date":"2025-05-16","current":-0.033516,"twenty":-0.647743,"median":-0.11053,"eighty":-0.064788,"marketCap":5581169},{"date":"2025-05-23","current":-0.045648,"twenty":-0.63835,"median":-0.110157,"eighty":-0.064588,"marketCap":6392975},{"date":"2025-05-30","current":-0.055226,"twenty":-0.62709,"median":-0.109384,"eighty":-0.063348,"marketCap":7734397},{"date":"2025-06-06","current":-0.058802,"twenty":-0.622492,"median":-0.108696,"eighty":-0.062794,"marketCap":8235186},{"date":"2025-06-13","current":-0.071516,"twenty":-0.600613,"median":-0.107668,"eighty":-0.063175,"marketCap":10015767},{"date":"2025-06-20","current":-0.065556,"twenty":-0.566039,"median":-0.107023,"eighty":-0.063313,"marketCap":9181119},{"date":"2025-06-27","current":-0.056815,"twenty":-0.557298,"median":-0.10387,"eighty":-0.062794,"marketCap":7956970},{"date":"2025-07-03","current":-0.05761,"twenty":-0.555758,"median":-0.101756,"eighty":-0.062399,"marketCap":8068256},{"date":"2025-07-11","current":-0.062378,"twenty":-0.541366,"median":-0.099933,"eighty":-0.061976,"marketCap":8735974},{"date":"2025-07-18","current":-0.064364,"twenty":-0.529937,"median":-0.097675,"eighty":-0.061583,"marketCap":9014190},{"date":"2025-07-25","current":-0.064761,"twenty":-0.520715,"median":-0.095947,"eighty":-0.061819,"marketCap":9069833},{"date":"2025-08-01","current":-0.061186,"twenty":-0.513446,"median":-0.092228,"eighty":-0.061583,"marketCap":8569045},{"date":"2025-08-06","current":-0.060788,"twenty":-0.511335,"median":-0.090759,"eighty":-0.061265,"marketCap":8513401}],"updateTime":1754622612329},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TRAW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548380632","title":"BRIEF-Nora Brennan Resigns As Traws Pharma's Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2548380632","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548380632?lang=en_us&edition=fundamental","pubTime":"2025-07-04 05:12","pubTimestamp":1751577161,"startTime":"0","endTime":"0","summary":"BRIEF-Nora Brennan Resigns As Traws Pharma's Interim CFOJuly 3  - Traws Pharma Inc TRAW.O:TRAWS PHARMA INC - NORA BRENNAN RESIGNS AS INTERIM CFO EFFECTIVE JULY 5 - SEC FILINGTRAWS PHARMA INC - CHARLES PARKER APPOINTED AS INTERIM CFO EFFECTIVE JULY 5 - SEC FILINGFurther company coverage: TRAW.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nFWN3T00I6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2548380572","title":"Traws Pharma Inc. Announces Departure of Interim CFO Nora Brennan and Appointment of Charles Parker as Successor","url":"https://stock-news.laohu8.com/highlight/detail?id=2548380572","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548380572?lang=en_us&edition=fundamental","pubTime":"2025-07-04 05:09","pubTimestamp":1751576951,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has announced a change in its management team. Nora Brennan has resigned from her position as Interim Chief Financial Officer, effective July 5, 2025. Charles Parker has been appointed by the Board as the new Interim Chief Financial Officer, effective the same date. Parker will serve in a non-employee consultant capacity, with a consulting agreement to be finalized soon.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nNDL5DwCBd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2547098943","title":"BRIEF-Traws Pharma Advances Antiviral Pipeline With Multiple Regulatory Submissions","url":"https://stock-news.laohu8.com/highlight/detail?id=2547098943","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547098943?lang=en_us&edition=fundamental","pubTime":"2025-06-30 18:32","pubTimestamp":1751279521,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Advances Antiviral Pipeline With Multiple Regulatory SubmissionsJune 30 (Reuters) - Traws Pharma Inc TRAW.O:TRAWS PHARMA ADVANCES ANTIVIRAL PIPELINE WITH MULTIPLE REGULATORY SUBMISS","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nFWN3SX0EK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2538562469","title":"BRIEF-Traws Pharma Announces Receipt Of FDA Guidance On Tivoxavir Marboxil, Plans For Pursuing Stockpiling For Pandemic Preparedness","url":"https://stock-news.laohu8.com/highlight/detail?id=2538562469","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538562469?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:43","pubTimestamp":1748349801,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Announces Receipt Of FDA Guidance On Tivoxavir Marboxil, Plans For Pursuing Stockpiling For Pandemic PreparednessMay 27 (Reuters) - Traws Pharma Inc TRAW.O:TRAWS PHARMA ANNOUNCES RE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nFWN3RZ1GW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2535841620","title":"BRIEF-Traws Pharma Reports First Quarter 2025 Results And Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2535841620","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535841620?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:40","pubTimestamp":1747309208,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Reports First Quarter 2025 Results And Business HighlightsTraws Pharma Inc TRAW.O:TRAWS PHARMA REPORTS FIRST QUARTER 2025 RESULTS AND BUSINESS HIGHLIGHTSSource text: ID:nGNX3SXCyTFurther company coverage: TRAW.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nTUA1YNPXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2535846359","title":"Traws Pharma Q1 EPS $2.09 Beats $(8.04) Estimate, Sales $57.00K Miss $60.00K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535846359","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535846359?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:12","pubTimestamp":1747307555,"startTime":"0","endTime":"0","summary":"Traws Pharma (NASDAQ:TRAW) reported quarterly earnings of $2.09 per share which beat the analyst consensus estimate of $(8.04) by 126 percent. This is a 135.3 percent increase over losses of $(5.92) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45432633/traws-pharma-q1-eps-2-09-beats-8-04-estimate-sales-57-00k-miss-60-00k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW"],"gpt_icon":0},{"id":"2535845952","title":"Traws Pharma Inc. Reports Q1 2025 Results: Revenue Steady at $57K, Net Income Soars to $21.5M, EPS at $2.17","url":"https://stock-news.laohu8.com/highlight/detail?id=2535845952","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535845952?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:02","pubTimestamp":1747306971,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL7G7GyY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW"],"gpt_icon":0},{"id":"2523941200","title":"Press Release: Traws Pharma Reports Full Year 2024 Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2523941200","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523941200?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:00","pubTimestamp":1743426000,"startTime":"0","endTime":"0","summary":"Tivoxavir marboxil's potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data. Ongoing FDA interaction to align on path forward for tivoxavir marboxil, including potential for accelerated approval utilizing the \"Animal Rule\". Cash Runway to support planned operations into Q1 2026. Investor Update call today, March 31, 2025 at 10:00 AM ET. NEWTOWN, Pa., March 31, 2025  -- Traws Pharma, Inc.  , a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results for the year ended December 31, 2024 and provided recent business highlights, with updates to the Company's investigational programs including lead product candidate, tivoxavir marboxil  in development for bird flu, and ratutrelvir in development for COVID.-- Bird flu: Finalize formulation and CMC scale up","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BNTX","BK4218","PK","BK4007","BK4568","BK4548","BK4585","TRAW","BK4181","BK4535","BK4588","CEO","BK4139"],"gpt_icon":0},{"id":"2523541635","title":"Traws Pharma CEO Werner Cautreels Retires, Chair Iain Duke Succeeds on Interim Basis","url":"https://stock-news.laohu8.com/highlight/detail?id=2523541635","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523541635?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:58","pubTimestamp":1743195525,"startTime":"0","endTime":"0","summary":"Traws Pharma  late Friday said Werner Cautreels will retire as chief executive officer after the biopharmaceutical company completes and files its 2024 annual report, expected by Monday.Cautreels will be succeeded on an interim basis by Iain D. Dukes, Traws board chair. Dukes will continue as board chair.Cautreels also will remain a member of the Traws board and work as a special adviser at the company over the next 12 months, it said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2523989633","title":"Traws Pharma CEO Werner Cautreels retires, Iain Dukes named interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2523989633","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523989633?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:35","pubTimestamp":1743194129,"startTime":"0","endTime":"0","summary":"Traws Pharma (TRAW) announced the retirement of Werner Cautreels, CEO, effective on or about close of business on March 31 after the company files ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/traws-pharma-ceo-werner-cautreels-retires-iain-dukes-named-interim-ceo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/traws-pharma-ceo-werner-cautreels-retires-iain-dukes-named-interim-ceo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2523633532","title":"Traws Pharma Announces Management Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2523633532","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523633532?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:30","pubTimestamp":1743193800,"startTime":"0","endTime":"0","summary":"Werner Cautreels, PhD, to retire as CEO, while continuing as a Board Member. Iain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO. NEWTOWN, Pa., March 28, 2025  -- Traws Pharma, Inc.  , a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer , effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assume the role of Interim CEO. In addition to his new responsibilities, Dr. Dukes will continue to serve as Traws’ Chairman.Dr. Dukes has held leadership roles in public and private biopharmaceutical companies, leveraging vast experience in corporate, strategic and product development. Dr. Cautreels will continue in his role as a member of the Traws Board of Directors and trans","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/traws-pharma-announces-management-updates-203000831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IKNA","IOVA","TRAW","BK4139","CEO"],"gpt_icon":1},{"id":"2522769548","title":"Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates  Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2522769548","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522769548?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:30","pubTimestamp":1742988600,"startTime":"0","endTime":"0","summary":"Event to highlight the differentiated features of Traws oral small molecule product candidates: Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease inhibitor for Bird FluRatutrelvir, a main ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/26/3049529/0/en/Traws-Pharma-to-Host-Investor-Event-on-Bird-Flu-and-COVID-Product-Candidates-Virtual-Event-to-be-Held-on-Monday-March-31-2025-at-10-00-AM-ET.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW","BK4581","BK4568","BNTX","BK4535","BK4590","PK","BK4181","BK4218","BK4588","BK4561","AM","BK4144","ET","BK4551","CDC","BK4585","HST","BK4548","BK4139"],"gpt_icon":0},{"id":"2522075303","title":"Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR","url":"https://stock-news.laohu8.com/highlight/detail?id=2522075303","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522075303?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:30","pubTimestamp":1742902200,"startTime":"0","endTime":"0","summary":"Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk of long COVID due to a longer treatment regimen. Preparations are underway for FDA interactions and initiation of Phase 2 studies. “We believe ratutrelvir has the potential to be a highly differentiated, broadly active treatment for COVID. Preparations are underway to meet with the FDA to align on a path forward and initiate Phase 2 studies,” noted Werner Cautreels, PhD, Chief Executive Officer for Traws Pharma. “We plan to host an Investor Event on Mo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/traws-pharma-covid-19-candidate-113000124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4588","BK4139","BK4535","BK4007","BK4585","PK","BK4181","CDC","TRAW","BK4551","BK4548","BK4568","BNTX"],"gpt_icon":0},{"id":"2521746248","title":"Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates","url":"https://stock-news.laohu8.com/highlight/detail?id=2521746248","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521746248?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:00","pubTimestamp":1742814000,"startTime":"0","endTime":"0","summary":"Tivoxavir marboxil (TXM), administered as a single dose in non-human primates, significantly reduced lung viremia and prevented weight loss, two key measures of antiviral activity in preclinical bird ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047706/0/en/Traws-Pharma-Antiviral-Bird-Flu-Program-Tivoxavir-Marboxil-Shows-Positive-Data-in-Non-human-Primates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDC","BK4007","TRAW"],"gpt_icon":0},{"id":"2521404409","title":"BRIEF-Traws Pharma Presents Positive Data For TXM As Bird Flu Treatment At ICAR","url":"https://stock-news.laohu8.com/highlight/detail?id=2521404409","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521404409?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:03","pubTimestamp":1742554987,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Presents Positive Data For TXM As Bird Flu Treatment At ICARMarch 21 (Reuters) - Traws Pharma Inc TRAW.O:TRAWS PHARMA INC - PRESENTS POSITIVE DATA FOR TXM AS BIRD FLU TREATMENT AT ICARSource text: ID:nGNX96RXJBFurther company coverage: TRAW.O ((Reuters.Briefs@thomsonreuters.com))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nFWN3Q4022:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2521047884","title":"Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR","url":"https://stock-news.laohu8.com/highlight/detail?id=2521047884","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521047884?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:00","pubTimestamp":1742554800,"startTime":"0","endTime":"0","summary":"Poster underscores Tivoxavir Marboxil’s potential for the treatment of bird flu, supported by 100% survival in a rodent challenge model, potent suppression of resistant viruses and Phase 1 data. “We were pleased to have the opportunity to share the promising TXM results in bird flu with the international antiviral community during the poster session at ICAR. We look forward to updating investors on Traws’ antiviral programs during a virtual event on Monday, March 31, 2025 at 10:00 AM ET, said Werner Cautreels, PhD, Chief Executive Officer of Traws Pharma.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/traws-pharma-bird-flu-drug-110000200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2518789849","title":"BRIEF-Traws Pharma Enters $50 Million ATM Agreement With Citizens JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2518789849","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518789849?lang=en_us&edition=fundamental","pubTime":"2025-03-11 05:35","pubTimestamp":1741642539,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Enters $50 Million ATM Agreement With Citizens JMP SecuritiesMarch 10 (Reuters) - Traws Pharma Inc TRAW.O:TRAWS PHARMA INC - ENTERS $50 MILLION ATM AGREEMENT WITH CITIZENS JMP SECURITIESFurther company coverage: TRAW.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2516687768","title":"Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil","url":"https://stock-news.laohu8.com/highlight/detail?id=2516687768","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516687768?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:00","pubTimestamp":1741003200,"startTime":"0","endTime":"0","summary":"NEWTOWN, Pa., March  03, 2025  (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035447/0/en/Traws-Pharma-Reports-Positive-Results-from-An-Accepted-Bird-Flu-Model-for-Anti-Viral-Candidate-Tivoxavir-Marboxil.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CDC","TRAW"],"gpt_icon":0},{"id":"2516684649","title":"BRIEF-Traws Pharma Reports Positive Results From Accepted Bird Flu Model For Anti-Viral Candidate, Tivoxavir Marboxil","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684649","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516684649?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:18","pubTimestamp":1741000710,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Reports Positive Results From Accepted Bird Flu Model For Anti-Viral Candidate, Tivoxavir MarboxilMarch 3  - Traws Pharma TRAW.O:TRAWS PHARMA: REPORTS POSITIVE RESULTS FROM ACCEPTED BIRD FLU MODEL FOR ANTI-VIRAL CANDIDATE, TIVOXAVIR MARBOXILTRAWS PHARMA: TOPLINE DATA FROM FERRET MODEL TESTING SHOW THAT TIVOXAVIR MARBOXIL HAS POTENTIAL TO INHIBIT DISEASE AFTER BIRD FLU INFECTIONTRAWS PHARMA: CONDUCTING SIMILAR CHALLENGE STUDY IN NON-HUMAN PRIMATES, WITH DATA EXPECTED IN Q1 2025Source text: [ID:]Further company coverage: TRAW.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM024:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2514913323","title":"Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2514913323","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514913323?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:00","pubTimestamp":1740744000,"startTime":"0","endTime":"0","summary":"NEWTOWN, Pa., Feb. 28, 2025  -- Traws Pharma, Inc.  , a clinical stage biopharmaceutical company developing oral small molecules for the treatment of respiratory viral diseases, announced today that it has received confirmation from Nasdaq that Traws has regained compliance with the minimum stockholders’ equity requirements of Nasdaq Listing Rule 5550, which requires listed companies to maintain a minimum of $2.5 million in stockholders’ equity. Accordingly, Traws common stock will continue to be listed and trade on The NASDAQ Capital Market under the symbol “TRAW”.Traws is committed to delivering novel compounds for unmet medical needs using state-of-t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/traws-pharma-regains-compliance-nasdaq-120000952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210149790.SGD","LU2210150020.SGD","BK4215","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","QID","BK4007","TRAW","BK4585","BK4588",".IXIC","IE00BGHQF748.EUR","BK4112","QLD","TQQQ","IE00BKPKM429.USD","USAW.SI","LU2095319765.USD","NVIW.SI","NDAQ","SQQQ","USJW.SI","TSYW.SI","EQR","NQmain","MNQmain","PSQ"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}